3
Oct 6 (Reuters) – * EISAI AND BIOGEN ANNOUNCE U.S. AVAILABILITY OF LEQEMBI® IQLIK™ (LECANEMAB-IRMB) SUBCUTANEOUS INJECTION MAINTENANCE DOSE FOR TREATMENT OF EARLY ALZHEIMER’S DISEASE Source text:
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
